Abivax SA, a prominent biotechnology company headquartered in Paris, France, continues to make significant strides in the healthcare sector, particularly in the development of anti-viral therapies and therapeutic vaccines. As of December 4, 2025, the company’s stock closed at 94.3 EUR, reflecting a robust market presence with a market capitalization of 7.27 billion EUR. Despite a challenging financial landscape, evidenced by a price-to-earnings ratio of -30.55, Abivax SA’s innovative pipeline and strategic partnerships underscore its potential for future growth.
The company’s flagship product, ABX 464, is currently in Phase II clinical trials and aims to provide a sustained viral remission or functional cure for patients with HIV/AIDS. This development is particularly noteworthy as it represents a significant advancement in the treatment of a global health challenge. Additionally, ABX 203, a therapeutic vaccine candidate, is progressing through Phase IIb/III trials for the treatment of chronic hepatitis B, further solidifying Abivax SA’s commitment to addressing infectious diseases.
ABX 196, an art immune enhancer candidate, has successfully completed Phase I clinical trials for iNKT cells, showcasing the company’s innovative approach to immune modulation. Beyond these primary products, Abivax SA is also developing vaccines for typhoid, meningitis B and C, and leptospirosis, expanding its portfolio to address a range of infectious diseases prevalent in Asia and Latin America.
The company’s pre-clinical programs are equally promising, with ABX 220 targeting Dengue fever, ABX 544 focusing on Ebola treatment through polyclonal antibodies, and ABX 311 aimed at Chikungunya. These initiatives highlight Abivax SA’s proactive approach to emerging infectious threats.
Strategic collaborations play a crucial role in Abivax SA’s success. The company has established license contracts with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute. Additionally, its partnership with the Cuban Centro de Ingenia Genetica y de Biotecnologia underscores its commitment to leveraging global expertise in biotechnology.
Incorporated in 2013, Abivax SA has rapidly evolved into a key player in the biotechnology sector, with its stock traded on the NYSE Euronext Paris. As the company continues to advance its clinical trials and expand its therapeutic offerings, it remains well-positioned to address the pressing healthcare needs of underserved regions, particularly in Asia and Latin America. With a forward-looking perspective, Abivax SA is poised to make significant contributions to global health, driven by its innovative research and strategic partnerships.
